Document is current
Any future updates will be listed below
-
Authors
Li, Jia
Chaurasiya, Shyambabu
Sun, Guihua https://orcid.org/0000-0001-7337-3543
Cui, Qi
Ye, Peng
Qin, Yue https://orcid.org/0000-0003-4277-3602
Zhou, Tao
Wang, Xiuli https://orcid.org/0000-0001-5964-4327
Fong, Yuman https://orcid.org/0000-0002-8934-9959
Maus, Marcela V. https://orcid.org/0000-0002-7578-0393
Shi, Yanhong https://orcid.org/0000-0002-3938-5839
- License Information
-
More Information
Article History
Received: 27 March 2025
Accepted: 10 March 2026
First Online: 9 April 2026
Competing interests
: S.C. is a consultant to Imugene Ltd. Y.F. is a paid scientific consultant for Medtronics, LivsMed, Imugene, Boston Scientific, Vergent, Eureka Therapeutics; receives royalties for inventions from Merck, XDemics, and Imugene Ltd; and owns the patent for CF33-Ovs licensed to Imugene Ltd. M.V.M. is an inventor on patents related to adoptive cell therapies, held by Massachusetts General Hospital (some licensed to Promab and Luminary) and University of Pennsylvania (some licensed to Novartis). M.V.M. receives Grant/Research support from BMS, Kite Pharma, Sobi. M.V.M. holds Equity in Altido Therapeutics. M.V.M. is a compensated Consultant for A2Bio, Adaptimmune, Alexion, Astellas, AstraZeneca, BMS, Cabaletta Bio, In8bio, KSQ, and Lumicks.
